Nicolas Sayegh: How Biomarker-Driven, Rational Combos May Unlock ICI Potential in mCRPC?
Nicolas Sayegh, Genitourinary Oncology Research Fellow at Huntsman Cancer Institute, shared a post on X:
“Just in Journal of Clinical Oncology: We explore how biomarker-driven, rational combos may unlock ICI potential in mCRPC prostate cancer. Plus data showing responses in MMRD, HRD, or high inflammatory infiltrates.”
Sumanta Pal, Vice Chair of Academic Affairs at City of Hope, shared City of Hope’s post by Nicolas Sayegh, adding:
“A beautiful manuscript from Nicolas Sayegh and Zeynep Irem Ozay with mentorship from Neeraj Agarwal and Tian Zhang – must read for anyone interested in Prostate Cancer.”
Title: Precision and Combination Strategies for Immune Checkpoint Inhibitors in Prostate Cancer
Authors: Nicolas Sayegh, Zeynep Irem Ozay, Tian Zhang, Neeraj Agarwal
Read the Full Article.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023